Pharmacokinetic Models: Comparison and Selection Criterion
Coronary Artery Disease I: Introduction
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Coronary Artery Disease IV: Preventive Measures
Model Approaches for Pharmacokinetic Data: Physiological Models
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Nov 16, 2025

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Steven A Grover1, Hiba Jekki1, Mohammed Kaouache1
1McGill Comprehensive Health Improvement Program, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
Cardiovascular risk assessment improves understanding of future cardiovascular disease (CVD) risk and aids in managing hypertension and dyslipidemia. It should initiate patient discussions on CVD risks and promote adherence to healthy habits and treatments.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: